High-dose donor bone marrow infusions to enhance allograft survival

The effect of timing

Camillo Ricordi, Theodore Karatzas, Jose Nery, Marc Webb, Gennaro Selvaggi, Luis Fernandez, Farrukh A. Khan, Phillip Ruiz, Eugene R Schiff, Leslie Olson, Hugo Fernandez, Judy Bean, Violet Esquenazi, Joshua Miller, Andreas G. Tzakis

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

Background. The development of strategies to enhance survival of transplanted organs and to potentially lower or even discontinue immunosuppressive therapy would represent a significant advance in posttransplant patient care. The aim of this clinical trial was to determine the effect of timing and dose of peripheral donor bone marrow cell (DBMC) infusion on graft and patient survival after liver transplantation. Methods. DBMC, obtained from vertebral bodies, were administered in 101 recipients of liver allografts (OLTX). There were 107 patients for whom DBMC could not be obtained; they received OLTX alone (controls). A total of 5 x 108/kg DBMC were infused at day 0 (group 1; n=9); at days 0 and 11 (group 2; n=26); or at days 5 and 11 (group 3; n=26). In group 4 (n=40), patients received up to five infusions of 2 x 108/kg DBMC at days 5, 14, 21, 28, and 90 after OLTX. Results. When the results from patients receiving two or more DBMC infusions (groups 2, 3, and 4) are considered, both patient and graft survival were significantly improved compared with the control group (P=0.02 and P=0.01, respectively). In groups 3 and 4, 88.5% and 95% of patients were alive with mean follow-up of 536 and 265 days, respectively, compared with 77.6% of patients in the control group (average follow-up of 452 days) (P=0.02). Graft survival was also significantly improved in groups 3 (88.5%) and 4 (92.5%), compared with the controls (72%) (P=0.007). Conclusions. The results suggest that dose and timing of DBMC infusions may be important variables affecting allograft survival. A randomized prospective trial is now in progress to compare group 3 DBMC infusion protocol with controls receiving OLTX alone.

Original languageEnglish
Pages (from-to)7-11
Number of pages5
JournalTransplantation
Volume63
Issue number1
DOIs
StatePublished - Jan 15 1997

Fingerprint

Bone Marrow Cells
Allografts
Bone Marrow
Tissue Donors
Graft Survival
Tissue Survival
Control Groups
Immunosuppressive Agents
Liver Transplantation
Patient Care
Clinical Trials
Liver

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

High-dose donor bone marrow infusions to enhance allograft survival : The effect of timing. / Ricordi, Camillo; Karatzas, Theodore; Nery, Jose; Webb, Marc; Selvaggi, Gennaro; Fernandez, Luis; Khan, Farrukh A.; Ruiz, Phillip; Schiff, Eugene R; Olson, Leslie; Fernandez, Hugo; Bean, Judy; Esquenazi, Violet; Miller, Joshua; Tzakis, Andreas G.

In: Transplantation, Vol. 63, No. 1, 15.01.1997, p. 7-11.

Research output: Contribution to journalArticle

Ricordi, C, Karatzas, T, Nery, J, Webb, M, Selvaggi, G, Fernandez, L, Khan, FA, Ruiz, P, Schiff, ER, Olson, L, Fernandez, H, Bean, J, Esquenazi, V, Miller, J & Tzakis, AG 1997, 'High-dose donor bone marrow infusions to enhance allograft survival: The effect of timing', Transplantation, vol. 63, no. 1, pp. 7-11. https://doi.org/10.1097/00007890-199701150-00003
Ricordi, Camillo ; Karatzas, Theodore ; Nery, Jose ; Webb, Marc ; Selvaggi, Gennaro ; Fernandez, Luis ; Khan, Farrukh A. ; Ruiz, Phillip ; Schiff, Eugene R ; Olson, Leslie ; Fernandez, Hugo ; Bean, Judy ; Esquenazi, Violet ; Miller, Joshua ; Tzakis, Andreas G. / High-dose donor bone marrow infusions to enhance allograft survival : The effect of timing. In: Transplantation. 1997 ; Vol. 63, No. 1. pp. 7-11.
@article{bc827830c57d457b922dcea17300fb0a,
title = "High-dose donor bone marrow infusions to enhance allograft survival: The effect of timing",
abstract = "Background. The development of strategies to enhance survival of transplanted organs and to potentially lower or even discontinue immunosuppressive therapy would represent a significant advance in posttransplant patient care. The aim of this clinical trial was to determine the effect of timing and dose of peripheral donor bone marrow cell (DBMC) infusion on graft and patient survival after liver transplantation. Methods. DBMC, obtained from vertebral bodies, were administered in 101 recipients of liver allografts (OLTX). There were 107 patients for whom DBMC could not be obtained; they received OLTX alone (controls). A total of 5 x 108/kg DBMC were infused at day 0 (group 1; n=9); at days 0 and 11 (group 2; n=26); or at days 5 and 11 (group 3; n=26). In group 4 (n=40), patients received up to five infusions of 2 x 108/kg DBMC at days 5, 14, 21, 28, and 90 after OLTX. Results. When the results from patients receiving two or more DBMC infusions (groups 2, 3, and 4) are considered, both patient and graft survival were significantly improved compared with the control group (P=0.02 and P=0.01, respectively). In groups 3 and 4, 88.5{\%} and 95{\%} of patients were alive with mean follow-up of 536 and 265 days, respectively, compared with 77.6{\%} of patients in the control group (average follow-up of 452 days) (P=0.02). Graft survival was also significantly improved in groups 3 (88.5{\%}) and 4 (92.5{\%}), compared with the controls (72{\%}) (P=0.007). Conclusions. The results suggest that dose and timing of DBMC infusions may be important variables affecting allograft survival. A randomized prospective trial is now in progress to compare group 3 DBMC infusion protocol with controls receiving OLTX alone.",
author = "Camillo Ricordi and Theodore Karatzas and Jose Nery and Marc Webb and Gennaro Selvaggi and Luis Fernandez and Khan, {Farrukh A.} and Phillip Ruiz and Schiff, {Eugene R} and Leslie Olson and Hugo Fernandez and Judy Bean and Violet Esquenazi and Joshua Miller and Tzakis, {Andreas G.}",
year = "1997",
month = "1",
day = "15",
doi = "10.1097/00007890-199701150-00003",
language = "English",
volume = "63",
pages = "7--11",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - High-dose donor bone marrow infusions to enhance allograft survival

T2 - The effect of timing

AU - Ricordi, Camillo

AU - Karatzas, Theodore

AU - Nery, Jose

AU - Webb, Marc

AU - Selvaggi, Gennaro

AU - Fernandez, Luis

AU - Khan, Farrukh A.

AU - Ruiz, Phillip

AU - Schiff, Eugene R

AU - Olson, Leslie

AU - Fernandez, Hugo

AU - Bean, Judy

AU - Esquenazi, Violet

AU - Miller, Joshua

AU - Tzakis, Andreas G.

PY - 1997/1/15

Y1 - 1997/1/15

N2 - Background. The development of strategies to enhance survival of transplanted organs and to potentially lower or even discontinue immunosuppressive therapy would represent a significant advance in posttransplant patient care. The aim of this clinical trial was to determine the effect of timing and dose of peripheral donor bone marrow cell (DBMC) infusion on graft and patient survival after liver transplantation. Methods. DBMC, obtained from vertebral bodies, were administered in 101 recipients of liver allografts (OLTX). There were 107 patients for whom DBMC could not be obtained; they received OLTX alone (controls). A total of 5 x 108/kg DBMC were infused at day 0 (group 1; n=9); at days 0 and 11 (group 2; n=26); or at days 5 and 11 (group 3; n=26). In group 4 (n=40), patients received up to five infusions of 2 x 108/kg DBMC at days 5, 14, 21, 28, and 90 after OLTX. Results. When the results from patients receiving two or more DBMC infusions (groups 2, 3, and 4) are considered, both patient and graft survival were significantly improved compared with the control group (P=0.02 and P=0.01, respectively). In groups 3 and 4, 88.5% and 95% of patients were alive with mean follow-up of 536 and 265 days, respectively, compared with 77.6% of patients in the control group (average follow-up of 452 days) (P=0.02). Graft survival was also significantly improved in groups 3 (88.5%) and 4 (92.5%), compared with the controls (72%) (P=0.007). Conclusions. The results suggest that dose and timing of DBMC infusions may be important variables affecting allograft survival. A randomized prospective trial is now in progress to compare group 3 DBMC infusion protocol with controls receiving OLTX alone.

AB - Background. The development of strategies to enhance survival of transplanted organs and to potentially lower or even discontinue immunosuppressive therapy would represent a significant advance in posttransplant patient care. The aim of this clinical trial was to determine the effect of timing and dose of peripheral donor bone marrow cell (DBMC) infusion on graft and patient survival after liver transplantation. Methods. DBMC, obtained from vertebral bodies, were administered in 101 recipients of liver allografts (OLTX). There were 107 patients for whom DBMC could not be obtained; they received OLTX alone (controls). A total of 5 x 108/kg DBMC were infused at day 0 (group 1; n=9); at days 0 and 11 (group 2; n=26); or at days 5 and 11 (group 3; n=26). In group 4 (n=40), patients received up to five infusions of 2 x 108/kg DBMC at days 5, 14, 21, 28, and 90 after OLTX. Results. When the results from patients receiving two or more DBMC infusions (groups 2, 3, and 4) are considered, both patient and graft survival were significantly improved compared with the control group (P=0.02 and P=0.01, respectively). In groups 3 and 4, 88.5% and 95% of patients were alive with mean follow-up of 536 and 265 days, respectively, compared with 77.6% of patients in the control group (average follow-up of 452 days) (P=0.02). Graft survival was also significantly improved in groups 3 (88.5%) and 4 (92.5%), compared with the controls (72%) (P=0.007). Conclusions. The results suggest that dose and timing of DBMC infusions may be important variables affecting allograft survival. A randomized prospective trial is now in progress to compare group 3 DBMC infusion protocol with controls receiving OLTX alone.

UR - http://www.scopus.com/inward/record.url?scp=0031034011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031034011&partnerID=8YFLogxK

U2 - 10.1097/00007890-199701150-00003

DO - 10.1097/00007890-199701150-00003

M3 - Article

VL - 63

SP - 7

EP - 11

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 1

ER -